Results, reality, and recalibration: Unpacking AI hype at SC...
SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
Newsletters and Deep Dive digital magazine
SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.
On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.
As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in
Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
Editor's Picks
Newsletters and Deep Dive
digital magazine